Related Experiment Video
Updated: Feb 14, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
Nivolumab in the treatment of advanced renal cell carcinoma
Malmaruha Arasaratnam1, Howard Gurney1,2
1Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, Australia.
Abstract:
Renal cell carcinoma (RCC) has typically been considered an immunogenic malignancy with responses seen to IL-2 and IFN-α. Response rates, however, were low and at the cost of considerable toxicity and as such, agents targeting angiogenesis have become the mainstay of treatment. Nivolumab is an immune checkpoint inhibitor targeting PD-1 thereby upregulating the host immune response against tumor cells. Nivolumab has emerged as a promising new therapy in advanced malignancies, and the first agent to show survival advantage in patients failing prior VEGFR-targeted therapy in metastatic RCC. This review summarizes the present evidence, toxicity profile, potential predictive biomarkers and promising future strategies with nivolumab in metastatic RCC.
Insights
Nivolumab, a PD-1 inhibitor, offers a survival advantage for patients with advanced renal cell carcinoma (RCC) who have not responded to prior treatments. This review covers its efficacy, safety, and future potential in metastatic RCC.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Renal cell carcinoma (RCC) is an immunogenic malignancy.
- Previous treatments like IL-2 and IFN-α had limited efficacy and high toxicity.
- Angiogenesis inhibitors became standard for advanced RCC.
Purpose of the Study:
- To review the evidence for nivolumab in metastatic RCC.
- To discuss its toxicity profile, predictive biomarkers, and future strategies.
Main Methods:
- Literature review of clinical trials and studies on nivolumab in metastatic RCC.
- Analysis of efficacy, safety, and biomarker data.
Main Results:
- Nivolumab is the first agent to demonstrate survival benefit in metastatic RCC patients after VEGFR-targeted therapy failure.
- It targets the PD-1 pathway to enhance anti-tumor immune response.
Conclusions:
- Nivolumab represents a significant advancement in treating advanced RCC.
- Further research into predictive biomarkers and combination strategies is warranted.
More Related Videos
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Related Concept Videos
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
02:22Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
01:20Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
01:23Renal Clearance
Renal clearance refers to the volume of plasma cleared of a specific substance, such as creatinine, per unit of time. To measure clearance, urine samples are collected over a 24-hour period during each bladder voiding, followed by a single blood sample at the...
00:56Extraction: Advanced Methods
01:08Renal Drug Clearance: Comparison Between Renal Excretion Methods
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...